首页 | 本学科首页   官方微博 | 高级检索  
     


Recurrence of cholestatic liver disease after living donor liver transplantation
Authors:Tamura Sumihito  Sugawara Yasuhiko  Kaneko Junichi  Togashi Junichi  Matsui Yuichi  Yamashiki Noriyo  Kokudo Norihiro  Makuuchi Masatoshi
Affiliation:1. Artificial Organ and Transplantation Division,Department of Surgery,Graduate School of Medicine,University of Tokyo,7-3-1 Hongo,Bunkyo-ku,Tokyo 113-8655,Japan
2. Japanese Red Cross Medical Center,4-1-22 Hiroo,Shibuya-ku,Tokyo 150-8935,Japan
Abstract:
End-stage liver disease,due to cholestatic liver diseases with an autoimmune background such as primary biliary cirrhosis(PBC)and primary sclerosing cholangitis(PSC),is considered a good indication for liver transplantation.Excellent overall patient and graft outcomes,based mostly on the experience from deceased donor liver ransplantation(DDLT),have been reported.Due to the limited number of oraan donations from deceased donors in most Asian countries,living donor liver transplantation(LDLT)is the mainstream treatment for end-stage liver disease,including that resulting from PBC and PSC.Although the initial experiences with LDLT for PBC and PSC seem satisfactory or comparable to that with DLT,some aspects,including the timing of transplantation,the risk of recurrent disease,and its long-term clinical implications,require further evaluation.Whether or not the long-term outcomes of LDLT from a biologically related donor are equivalent to that of DDLT requires further observations.The clinical course following LDLT may be affected by he genetic background shared between the recipient and the living related donor.(C)2008 The WJG Press.All rights reserved.
Keywords:Liver transplantation  Primary biliary cirrhosis  Primary sclerosing cholangitis  Living donor  Recurrence
本文献已被 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号